Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03582475
Title Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center

prostate neuroendocrine neoplasm

urethra cancer

prostate small cell carcinoma

ureter small cell carcinoma

urinary bladder small cell neuroendocrine carcinoma



Carboplatin + Docetaxel + Etoposide + Pembrolizumab

Cisplatin + Etoposide + Pembrolizumab


Carboplatin + Etoposide + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.